Evidence map›Paper›PMID 41844873›Full record

ArticleScientific reports2026

Genetic variants and serum biomarkers of CXCL8, MAP3K7, LTA/TNF, EXOC3L1, PROCR, and TRAF2 in Age-Related macular degeneration: associations with disease risk and therapeutic response.

Dzastina Cebatoriene, Alvita Vilkeviciute, Monika Duseikaite-Vidike, Enrika Pileckaite, Akvile Bruzaite, Loresa Kriauciuniene, Dalia Zaliuniene, Rasa Liutkeviciene

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dzastina CebatorieneMedical Academy, Lithuanian University of Health Sciences, A. Mickeviciaus St. 9, Kaunas, LT-44307, Lithuania.
Alvita VilkeviciuteNeuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu St. 2, Kaunas, LT-50161, Lithuania. alvita.vilkeviciute@lsmu.lt.
Monika Duseikaite-VidikeNeuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu St. 2, Kaunas, LT-50161, Lithuania.
Enrika PileckaiteNeuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu St. 2, Kaunas, LT-50161, Lithuania.
Akvile BruzaiteNeuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu St. 2, Kaunas, LT-50161, Lithuania.
Loresa KriauciunieneNeuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu St. 2, Kaunas, LT-50161, Lithuania.
Dalia ZaliunieneDepartment of Ophthalmology, Medical Academy, Lithuanian University of Health Sciences, Eiveniu St. 2, Kaunas, LT-50161, Lithuania.
Rasa LiutkevicieneNeuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu St. 2, Kaunas, LT-50161, Lithuania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in the aging population, it is a significant global health concern. Although anti-vascular endothelial growth factor (anti-VEGF) treatments are effective, not all patients respond to them fully. This study focuses on key single-nucleotide variants in the CXCL8 (rs2227306), MAP3K7 (rs157432), LTA/TNF (rs2229094), EXOC3L1 (rs868213), PROCR (rs867186), TRAF2 (rs10781522), and serum levels of these genes in AMD development and treatment response. It examines the genetic factors associated with susceptibility to AMD and how they influence response to therapy. The study investigates the relationships between specific genetic variations, serum protein levels, and both exudative and early AMD, as well as responses to anti-VEGF treatment. These findings may help guide risk assessment and personalized AMD therapies.

Indexed as

Macular DegenerationPolymorphism, Single NucleotideAgedBiomarkersFemaleGenetic Predisposition to DiseaseHumansInterleukin-8Lymphotoxin-alphaMaleTNF Receptor-Associated Factor 2Tumor Necrosis Factor-alphaVascular Endothelial Growth Factor ABiomarkersCXCL8 protein, humanInterleukin-8LTA protein, humanLymphotoxin-alphaTNF Receptor-Associated Factor 2Tumor Necrosis Factor-alphaVascular Endothelial Growth Factor AAMDAnti-VEGF therapyProtein levelsSNV analysis

Identifiers

PMID41844873
PMCPMC13129072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.